Clinical Trial

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2025 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-06-21; most recent amendment 2025-04-11.
Status change: Recruiting → Active, Not Recruiting 2025-04-11
Status change: Not Yet Recruiting → Recruiting 2023-06-23
Trial Details
NCT Number NCT05915351
Lead Sponsor University of Kansas Medical Center
Conditions Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer
Enrollment 28 participants
Start Date 2023-06-30
Primary Completion 2025-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-16